Moderna shares are trading higher by 3.1% Monday afternoon. The CDC reported a significant rise in acute respiratory ...
Moderna made a lot of money during the pandemic, but its post-pandemic prospects look bleak. Sales in 2025 could be down more than half from 2024 levels, according to Moderna's latest guidance ...
Moderna Inc. shares plunged after the company slashed its sales forecast for this year as it struggles with slow demand for its Covid and RSV vaccines. The Cambridge, Massachusetts-based company ...
Moderna laid out sales expectations for the coming year on Monday that were below even the much-diminished Wall Street expectations. The stock was falling 14% to $35.71 in premarket trading. Monday’s ...
Moderna's bird flu vaccine development, supported by a U.S. government grant, could be a game changer if the bird flu spreads ...
Drug maker Moderna's stock plunged more than 17% in pre-market trading on Monday after the company slashed its sales outlook by $1 billion. The company reported product sales of $3 to $3.1 billion ...
Biopharma executives were busy Monday, striking high-value deals and providing updates on cancer, obesity and vaccine ...
9don MSN
With a state grand jury report released Wednesday, Florida Gov. Ron DeSantis doubled down on the message he delivered often ...
Moderna, a leader in mRNA medicine, developed one of the earliest COVID-19 vaccines, with Spikevax being its first commercial product. The company's mRNA platform enables the development of ...
Moderna projects $1.5 billion-$2.5 billion in 2025 revenue, with cash and investments estimated at $6 billion by year-end. 2024 product sales are approximately $3 billion-$3.1 billion, driven by $ ...
Stock-plunging mRNA vaccine maker, already in bed with feds on vaccine royalties, says booster not "causally" related without ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback